Magazine

With use of cardiac implantable electronic devices on the rise, experts stress device selection, prophylactic antibiotics, pre-procedural protocols and post-implementation vigilance.

New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.

Ramping up the battle against cardiovascular disease in women represents a golden opportunity to move the needle on mortality.

In this magazine’s cover story, we examine the work that still needs to be done to improve women’s heart health. Despite significant progress, too many women aren’t even aware that heart disease is relevant to them, let alone their gender’s leading cause of death.

Smart technologies are often touted as the answer to some of cardiology’s greatest challenges. But where does hyperbole end and reality begin?

Patients with heart failure with preserved ejection fraction (HFpEF), who face a high mortality risk and do not respond to conventional therapies, are changing the way clinicians think about heart failure.

As TAVR continues to deliver success for patients and practices, questions about volume and access have emerged.

In a back-to-the-future move, a decades-old care delivery concept is gaining momentum.

It’s becoming evident that the Stark law is frustrating the move from volume to value. Experts expect changes that could allow health systems and practices to deploy better coordinated, team-based care and advanced alternative payment models.

Major cardiology associations joined forces to update the 2012 universal definition of myocardial infarction and standardize what constitutes a heart attack.

Machine learning tools will support physicians’ efforts to deliver better patient outcomes at lower costs.

Do you remember the anticipation around renal denervation? And then the ACC.14 presentation of the SYMPLICITY HTN-3 results, where the excitement about a new way to treat resistant hypertension seemed to crash?

Select an Issues